Taking the Brakes Off Targeted Protein Degradation

Chopra, 2019, A critical evaluation of the approaches to targeted protein degradation for drug discovery, Drug Discov. Today. Technol., 31, 5, 10.1016/j.ddtec.2019.02.002 Cohen, 2006, Sequence variations in PCSK9, low LDL, and protection against coronary heart disease, N. Engl. J. Med., 354, 1264, 10.1056/NEJMoa054013 Gechijian, 2018, Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands, Nat. Chem. Biol., 14, 405, 10.1038/s41589-018-0010-y Kwon, 2008, Molecular basis for LDL receptor recognition by PCSK9, Proc. Natl. Acad. Sci. USA, 105, 1820, 10.1073/pnas.0712064105 Neklesa, 2011, Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins, Nat. Chem. Biol., 7, 538, 10.1038/nchembio.597 Petrilli, 2020, From Screening to Targeted Degradation: Strategies for the Discovery and Optimization of Small Molecule Ligands for PCSK9, Cell Chem. Biol., 27, 32, 10.1016/j.chembiol.2019.10.002 Sabatine, 2017, Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease, N. Engl. J. Med., 376, 1713, 10.1056/NEJMoa1615664 Schreiber, 2019, A chemical biology view of bioactive small molecules and a binder-based approach to connect biology to precision medicines, Isr. J. Chem., 59, 52, 10.1002/ijch.201800113 Seidah, 2019, Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies, Cardiovasc. Res., 115, 510, 10.1093/cvr/cvz003 Shi, 2016, Boc3Arg-Linked Ligands Induce Degradation by Localizing Target Proteins to the 20S Proteasome, ACS Chem. Biol., 11, 3328, 10.1021/acschembio.6b00656 Zhang, 2017, Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists, Nat. Struct. Mol. Biol., 24, 848, 10.1038/nsmb.3453